A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome
A Phase I/II, Open Label, Single Dose Clinical Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD (Autologous cd34+ Cells Enriched With Blood Derived Mitochondria) in Pediatric Patients With Pearson Syndrome
Sponsor: Minovia Therapeutics Ltd.
This PHASE1/PHASE2 trial investigates Mitochondrial Diseases and Pearson Syndrome and is currently completed. Minovia Therapeutics Ltd. leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Enrolling By Invitation → Completed
-
Jan 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE1_PHASE2
▶ Show 7 earlier versions
-
Apr 2020 — Jul 2020 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Mar 2020 — Apr 2020 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Jun 2019 — Mar 2020 [monthly]
Enrolling By Invitation PHASE1_PHASE2
-
Mar 2019 — Jun 2019 [monthly]
Enrolling By Invitation PHASE1_PHASE2
Status: Not Yet Recruiting → Enrolling By Invitation · Phase: EARLY_PHASE1 → PHASE1_PHASE2
-
Jan 2019 — Mar 2019 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Minovia Therapeutics Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .